Eli Lilly and Company, AbCellera Biologics, Amgen, AstraZeneca, Genentech, and GlaxoSmithKline recieved approval from DOJ on July 23, 2020 to share information about manufacturing facilities and other information that could enable them to expedite the production of monoclonal antibody treatments that are determined to be safe and effective to treat COVID-19.
Phoenix-based biomedical innovator holds numerous patents and trademarks in the rapidly growing aesthetics industry
“Decathlon’s investment allows us to deliver these ground-breaking aesthetic treatments and products to providers and consumers and continue to build the most innovative solutions in the marketplace.”Continue reading
Calls for at least $75 billion in additional funding and the CDC to lead with testing protocols
Commits $100 Million in Rockefeller Foundation Funding for Global Coronavirus ResponseContinue reading
Whether you’re interested in tracking misinformation, flagging misinformation, or just want to show support for vaccines and science, you are needed now more than ever.
Ashison Analytics GEMExTra test detects rare NRG1 gene fusions in patients whose cancer is driven by this genomic alteration for potential matching to a clinical trialContinue reading
WASHINGTON, D.C. – The National Consumers League, the American Clinical Laboratory Association (ACLA) and America’s Health Insurance Plans (AHIP) joined nearly 50 leading stakeholders representing patients, employers, clinical laboratories, health insurance providers and other leaders from across health care community yesterday in sending a letter to congressional leadership requesting dedicated federal funding for the critical testing needed to reopen the country.Continue reading
Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation regenerative products derived from amniotic birth tissues, announced today first results from a large field study of RenoVō® for soft tissue and orthopedic horse injuries.
U.S. government placed an initial order of 100 million doses for $1.95 billion and can acquire up to 500 million additional doses
Americans to receive the vaccine for free consistent with U.S. government’s commitment for free access for COVID-19 vaccines
Pfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and efficacy trial later this month, seek regulatory review as early as October 2020, and manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021Continue reading
The Arizona Bioindustry Association, Inc. (AZBio) is issuing this Request for Proposals (RFP) to qualified firms to provide fundraising services to support the capitalization of the Arizona endowment within AZAdvances (www.azadvances.org). AZAdvances is a division of the Opportunity Through Entrepreneurship Foundation, a 501c3 public charity with offices at 107 S Southgate Drive, Chandler, AZ 85226.Continue reading
PHOENIX, AZ (July 17, 2020) — The Arizona Commerce Authority (ACA) announced today applications are being accepted for the 2020 Arizona Innovation Challenge (AIC) beginning Monday, August 3rd. The business plan competition is designed to advance innovation and technology commercialization opportunities in Arizona by helping early-stage ventures scale.Continue reading